Abstracts Archive - Page 1975 of 2607 - ACR Meeting Abstracts

Abstract Number: 1563 • 2015 ACR/ARHP Annual Meeting
Dyslipidemia and Hyperglycemia, Two Cardiometabolic Parameters, Independently Predict Poor Outcome in Early Rheumatoid Arthritis: Results from Espoir Cohort
Claire I. Daien¹, Jeremie Sellam², Nathalie Rincheval³, Bruno Fautrel⁴, Alain Saraux⁵, Francis Berenbaum⁶, Jacques Morel¹, Jean-Pierre Daures⁷ and Bernard Combe⁸, ¹Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²Department of Rheumatology, Assistance Publique – Hôpitaux de Paris, Saint-Antoine Hospital, Paris, France, ³Biostatistic, EA 2415, Epidemiology unit, Montpellier, France, ⁴Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, ⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁶Rheumatology and Paris VI University, Saint-Antoine Hospital, Paris, France, ⁷Biostatistic, EA 2415 Epidemiology unit, Montpellier, France, ⁸Rheumatology, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Previous studies showed that obesity in patients with rheumatoid arthritis (RA) is associated with higher disease activity. Beyond obesity, cardiometabolic disturbances may impact the…
Abstract Number: 1564 • 2015 ACR/ARHP Annual Meeting
Initiation of Disease Modifying Therapies and Subsequent Weight Change in Rheumatoid Arthritis
Joshua Baker¹, Brian Sauer², Kaleb Michaud³, Grant W. Cannon⁴, Said Ibrahim⁵, Liron Caplan⁶, Lisa A. Davis⁶, Amy C. Cannella⁷ and Ted R. Mikuls⁸, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Rheumatology & Immunology, University of Nebraska Medical Center and National Data Base for Rheumatic Diseases, Omaha, NE, ⁴Internal Medicine, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, ⁵Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Div of Rheumatology, Univ of CO Denver School of Med, Aurora, CO, ⁷Section of Rheumatology, University of Nebraska Med Ctr, Omaha, NE, ⁸University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Low body mass index (BMI) predicts adverse outcomes in rheumatoid arthritis (RA), in part due to weight loss among patients with severe disease and…
Abstract Number: 1565 • 2015 ACR/ARHP Annual Meeting
High Disease Activity over Time and Persistent Inflammation Are Associated with Increased Risk of Cardiovascular Disease in Patients with Early Rheumatoid Arthritis
Emil Rydell^1,2, Christina Book^1,2, Jan-Åke Nilsson^1,2, Minna Willim^1,2, Lennart T.H. Jacobsson^1,3 and Carl Turesson^1,4, ¹Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ³Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, ⁴Lund University, Rheumatology, Dept. of Clinical Sciences,, Malmö, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased rate of cardiovascular (CV) disease. Systemic inflammation has been implicated as a key factor behind CV…
Abstract Number: 1566 • 2015 ACR/ARHP Annual Meeting
The Impact of Severe Extra-Articular Manifestations and Patient Reported Outcome Measures on Cardiovascular Disease in Rheumatoid Arthritis
Lisa Theander¹, Jan-Åke Nilsson¹, Minna Willim^1,2, Britt-Marie Nyhäll-Wåhlin^1,3, Lennart T.H. Jacobsson^1,4 and Carl Turesson^1,5, ¹Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ³Department of Rheumatology, Falun Hospital, Falun, Sweden, ⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden, ⁵Lund University, Rheumatology, Dept. of Clinical Sciences,, Malmö, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of cardiovascular disease (CVD). Disease severity, including extra-articular rheumatoid arthritis (ExRA) manifestations, has previously been demonstrated…
Abstract Number: 1567 • 2015 ACR/ARHP Annual Meeting
Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting
Matthew Wong-Pack¹, Rod Rodjanapiches¹, Arthur Lau^1,2,3, George Ioannidis^1,3, Sally Wade⁴, Leslie Spangler⁴, Celia JF Lin⁴, Patrick Roy-Gayos¹, William G Bensen^1,3, Robert Bensen³ and Jonathan D Adachi^1,3, ¹McMaster University, Hamilton, ON, Canada, ²Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴Amgen Inc., Thousand Oaks, CA
Background/Purpose: Previous studies combining immunosuppressive biologics have shown an increased risk of infections. Few studies have examined the risk of infection with concurrent use of…
Abstract Number: 1568 • 2015 ACR/ARHP Annual Meeting
Cardiac Morphology and Function in Patients with Acute Coronary Syndrome Complicated with Rheumatoid Arthritis
Li-Li Pan¹ and Tian Wang², ¹Rheumatology and Immunology, Beijing Anzhen Hospital affiliated to Capital Medical University, Beijing, China, ²1. Department of Rheumatology and Immunology,, Beijing An Zhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China
Background/Purpose: Cardiovascular diseases are important contributors to the excess of overall morbidity and mortality in patients with rheumatoid arthritis (RA). The aim of this study…
Abstract Number: 1569 • 2015 ACR/ARHP Annual Meeting
Rituximab Efficacy in the Treatment of Diffuse Interstitial Lung Disease Associated with Rheumatoid Arthritis
Javier Narváez¹, Milagros Ricse², Juan José Alegre³, Gloria Albert Espi³, Carmen Gomez Vaquero⁴, Helena Borrell Paños², Eulalia Armengol², Joan Miquel Nolla², Susana Herrera⁵ and Maria Molina⁶, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, ⁴Department of Rheumatology, Hospital Universitario Bellvitge, Barcelona, Spain, ⁵Deparment of Pneumology, Hospital Universitario Dr Peset, Valencia, Spain, ⁶Department of Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To investigate the efficacy and safety of rituximab (RTX) in the the management of progressive rheumatoid arthritis related interstitial lung disease (RA-ILD). Methods: An…
Abstract Number: 1570 • 2015 ACR/ARHP Annual Meeting
End Stage Renal Disease (ESRD) in Patients with Rheumatoid Arthritis
Sunita Paudyal¹, Monique Bethel², Frances Yang¹, Alyce Oliver¹, Michael Skelton¹, Christopher Rice¹, Brian Le³, Shilpa Brown¹, Stanley Nahman¹ and Laura Carbone⁴, ¹Georgia Regents University, Augusta, GA, ²Internal Medicine, Georgia Regents University, Augusta, GA, ³Medicine, Georgia Regents University, Augusta, GA, ⁴Rheumatology, Georgia Regents University, Augusta, GA
Background/Purpose: Substantial progress has been made in the treatment of rheumatoid arthritis (RA) and life expectancy has increased. As the population of patients with RA…
Abstract Number: 1571 • 2015 ACR/ARHP Annual Meeting
How Substantive Is Heart Rate Variability As a Predictor of Anti-TNF Treatment Outcome for Inflammatory Arthritis?
Andrew Holman¹ and Edmund Ng², ¹Inmedix, Normandy Park, WA, ²Statistical Thinking, Seattle, WA
Background/Purpose: As rheumatologists search for new targets to improve immunosuppressive outcomes, the autonomic nervous system (ANS) as a co-factor in autoimmune disease expression has gained…
Abstract Number: 1572 • 2015 ACR/ARHP Annual Meeting
Plasma Apolipoprotein B48 Levels in Patients with Rheumatoid Arthritis: Evaluating Novel Cardiovascular Risk Factors
Deborah van Breukelen-van der Stoep¹, Derkjen van Zeben¹, Marijke de Vries², Boudewijn Klop², Noelle van der Meulen², Gert Jan van de Geijn³, Hans Janssen³, Pedro Valdivielso⁴, José Rioja⁴, José Ramirez-Bollero⁴, Mieke Hazes⁵, Erwin Birnie^6,7 and Manuel Castro Cabezas⁸, ¹Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ²Department of Internal Medicine, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ³Department of Clinical Chemistry, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁴Department of Internal Medicine and Dermatology, Hospital Virgen de la Victoria, Malaga, Spain, ⁵Department of Rheumatology, Erasmus Medical Centre Rotterdam, Rotterdam, Netherlands, ⁶Statistics and Education, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁷Insitute of Health Policy and Management, Erasmus University, Rotterdam, Netherlands, ⁸Department of Internal Medicine, Sint Francicscus Gasthuis, Rotterdam, Netherlands
Background/Purpose: Chylomicrons, with apolipoprotein (apo) B48 as a structural protein, induce leukocyte and complement activation and contribute to atherosclerosis. ApoB48 is higher in conditions associated…
Abstract Number: 1573 • 2015 ACR/ARHP Annual Meeting
Plasma Pentraxin 3 Concentration Is Associated with Progression of Radiographic Joint Damage but Not with Carotid Atherosclerosis in Female Patients with Rheumatoid Arthritis: Results from a 3-Year Prospective Study
Yu Asanuma¹, Yuki Shimada², Yoshimi Aizaki¹, Kazuhiro Yokota¹, Noritsune Kouzu³, Yoshitake Takebayashi⁴, Hisashi Noma⁴, Shinichi Kawai⁵ and Toshihide Mimura², ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Saitama Medical University, Saitama, Japan, ³Kouzu Orthopaedic Clinic, Chiba, Japan, ⁴The Institute of Statistical Mathematics, Tokyo, Japan, ⁵Div of Rheum/dept of Int Med, Toho Uni Sch of Med, Tokyo, Japan
Background/Purpose: Pentraxin 3 (PTX3) plays an important role in inflammation, immunity, and atherosclerosis. Plasma PTX3 level is recognized as a marker that responds to local…
Abstract Number: 1574 • 2015 ACR/ARHP Annual Meeting
Associations of Serum Anti-Malondialdehyde-Acetaldehyde (MAA) Antibodies with Cardiovascular and Respiratory Mortality in Men with Rheumatoid Arthritis
Bryant R. England¹, Geoffrey M. Thiele², Michael J. Duryee³, Lynell Klassen⁴, Jeremy Sokolove⁵, William H. Robinson⁶, Daniel Anderson⁷, Harlan Sayles⁷, Kaleb Michaud⁸, Liron Caplan⁹, Lisa A. Davis⁹, Grant W. Cannon¹⁰, Brian Sauer¹¹, E. Blair Solow¹², Andreas Reimold¹³, Gail S. Kerr¹⁴, Pascale Schwab¹⁵, Joshua F. Baker¹⁶ and Ted R. Mikuls¹⁷, ¹Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Research Services 151, Omaha VA Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, ⁵Division of Immunology and Rheumatology, Stanford University Medical Center, Mountain View, CA, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Rheumatology & Immunology, University of Nebraska Medical Center and National Data Base for Rheumatic Diseases, Omaha, NE, ⁹Div of Rheumatology, Univ of CO Denver School of Med, Aurora, CO, ¹⁰Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ¹¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ¹²Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹³Rheumatology, VAMC, University of Texas Southwestern Medical Center, Dallas, TX, ¹⁴VAMC, Georgetown University, Washington, DC, ¹⁵Div Arth & Rheum Dis, Oregon Health & Sci Univ OP09, Portland, OR, ¹⁶Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁷Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Mortality from cardiovascular (CV) and respiratory causes is increased in rheumatoid arthritis (RA). Predictive serologic biomarkers of these events are lacking. Previously, we have…
Abstract Number: 1575 • 2015 ACR/ARHP Annual Meeting
Serum Vascular Cell Adhesion Molecule-1 (VCAM-1) Levels Are Associated with Vascular Dysfunction and Increased Cardiovascular Risk in an Animal Model and Patients with Rheumatoid Arthritis
Ruth Davies¹, Daniela Iacono², Lauren A. Jordan¹, Jessica O Williams¹, Charlotte Rawlings¹, Derek Lang³, Anwen S. Williams¹ and Ernest H. Choy¹, ¹Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ²Department of Clinical and Experimental Medicine. Rheumatology Section. Second University of Naples, Naples, Italy, ³Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Mortality is increased in Rheumatoid arthritis (RA) patients mainly due to cardiovascular (CV) disease; however the biologic mechanisms are unknown. Increased CV risk in…
Abstract Number: 1576 • 2015 ACR/ARHP Annual Meeting
Effect of Conventional Synthetic and Biological Disease Modifying Anti-Rheumatic Drugs on the Immunogenicity of Hepatitis B Vaccine in Patients with Rheumatoid Arthritis
Samanan Intongkam¹, Rattapol Pakchotanon², Sumapa Chaiamnuay², Paijit Asavatanabodee² and Pongthorn Narongroeknawin², ¹Internal medicine, Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand, ²Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and Phramongkutklao College of Medicine, Bangkok, Thailand
Background/Purpose: Immunogenicity of pneumococcal and influenza vaccine in patients with rheumatoid arthritis (RA) have been assessed in many studies. However, the humoral immune response of…
Abstract Number: 1577 • 2015 ACR/ARHP Annual Meeting
Periodontal Evaluation Is Associated with Increased Likelihood of Achieving Low Disease Activity in Rheumatoid Arthritis with Methotrexate
Melanie Rohr¹, James R. O'Dell¹, Abhijeet Danve², Harlan Sayles¹, Geoffrey M. Thiele³, Jeffrey Payne⁴ and Ted R. Mikuls⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Research Services 151, Omaha VA Medical Center, Omaha, NE, ⁴College of Dentistry, University of Nebraska Medical Center, Lincoln, NE, ⁵Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) outcomes have improved substantially due to the development of new drug therapies, but also due to emphasis on early aggressive MTX…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].